- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07938528
Strategy of Intracoronary Imaging Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels (STENTLESS II)
Strategies of Intracoronary Imaging Guided Drug-coated Balloons (DCB) Versus Angiography Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels Trial (STENTLESS II)
A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Erli Zhang
- Phone Number: +86 18500853301
- Email: zhangerli@fuwaihospital.org
Study Locations
-
-
-
Beijing, China, 100037
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants must meet all of the following three criteria:
- Age ≥18 years;
- De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm;
- One or more trial target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment with DCB.
Exclusion Criteria:
Participants who meet any of the following conditions are not eligible for inclusion:
- Patients with hemodynamically unstable acute coronary syndrome
- Previous percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) on the target vessel within 12 months
- In-stent restenosis requiring revascularization
- Complex Coronary Bifurcation Lesions*
- Lesions with any of the following anatomical characteristics are presumably not suitable for DCB treatment:
1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a life expectancy of less than 1 year. 8. Known contraindication to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intracoronary imaging-Guided Drug-coated balloon strategy
DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria. |
In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed. |
|
Active Comparator: CAG-guided Drug-coated balloon strategy
In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment. |
For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Target vessel failure
Time Frame: 12 months
|
Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device success
Time Frame: 0 day (during index PCI)
|
|
0 day (during index PCI)
|
|
Procedure success
Time Frame: 7 days
|
Device success Freedom from in-hospital TVF |
7 days
|
|
Periprocedural complications
Time Frame: 48 hours
|
Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion |
48 hours
|
|
Incidence of cardiac death
Time Frame: 1, 12, 24, 36, and 60 months
|
Incidence of cardiac death |
1, 12, 24, 36, and 60 months
|
|
Incidence of target-vessel myocardial infarction
Time Frame: 1, 12, 24, 36, and 60 months
|
Incidence of target-vessel myocardial infarction |
1, 12, 24, 36, and 60 months
|
|
Incidence of clinically indicated target vessel revascularization
Time Frame: 1, 12, 24, 36, and 60 months
|
Incidence of clinically indicated target vessel revascularization |
1, 12, 24, 36, and 60 months
|
|
Patient-oriented composite endpoint (PoCE)
Time Frame: 1, 12, 24, 36, and 60 months
|
Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization |
1, 12, 24, 36, and 60 months
|
|
all-cause mortality
Time Frame: 1, 12, 24, 36, and 60 months
|
all-cause mortality |
1, 12, 24, 36, and 60 months
|
|
Any myocardial infarction
Time Frame: 1, 12, 24, 36, and 60 months
|
Any myocardial infarction |
1, 12, 24, 36, and 60 months
|
|
Any stroke
Time Frame: 1, 12, 24, 36, and 60 months
|
Any stroke |
1, 12, 24, 36, and 60 months
|
|
Any revascularization
Time Frame: 1, 12, 24, 36, and 60 months
|
Any revascularization |
1, 12, 24, 36, and 60 months
|
|
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)
Time Frame: 1,12, 24, 36, and 60 months
|
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC)) |
1,12, 24, 36, and 60 months
|
|
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)
Time Frame: 1, 12, 24, 36, and 60 months
|
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5) |
1, 12, 24, 36, and 60 months
|
|
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
Time Frame: 1, 12, 24, 36 and 60 months
|
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR |
1, 12, 24, 36 and 60 months
|
|
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
Time Frame: 1, 12, 24, 36 and 60 months
|
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events |
1, 12, 24, 36 and 60 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FW-ZEL-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.
IPD Sharing Time Frame
Beginning 36 months after publication of the primary study results and continuing for 5 years.
IPD Sharing Access Criteria
Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.